Stock ALLR ALLARITY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Allarity Therapeutics, Inc.

Equities

ALLR

US0167444019

Market Closed - Nasdaq
Other stock markets
 03:59:46 2024-05-29 pm EDT 		5-day change 1st Jan Change
0.5857 USD +1.83% Intraday chart for Allarity Therapeutics, Inc. +1.10% -94.69%
May. 24 Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial CI
May. 06 Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
AQ
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
AQ
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
AQ
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
AQ
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
AQ
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
AQ
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
AQ
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
AQ
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
AQ
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
AQ
Allarity Therapeutics : Material Agreement - Form 8-K
PU
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
AQ
Allarity Therapeutics to Present at Biomarkers 2024
AQ
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
AQ
Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic
AQ
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
AQ
Allarity Therapeutics to Present at Biomarkers Europe 2023
AQ
Allarity Therapeutics : Modification to Rights of Security Holders - Form 8-K
PU
Allarity Therapeutics : Material Agreement - Form 8-K
PU
PLOS ONE Publishes Data on Allarity Therapeutics DRP Companion Diagnostic for Dovitinib
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLR Stock
  4. News Allarity Therapeutics, Inc.
  5. Press Releases